PRECISION MEDICINE FOR RYR1-RELATED MYOPATHIES: A COMPREHENSIVE REVIEW OF GENE EDITING, PHARMACOLOGICAL INTERVENTIONS, AND SOCIETAL IMPLICATIONS
Authors:
- Magdalena FidelisMFMagdalena Fidelis
- Maria WojcieszekMWMaria Wojcieszek
- Katarzyna GondekKGKatarzyna Gondek
- Dominika GackaDGDominika Gacka
- Agnieszka ZalewskaAZAgnieszka Zalewska
- Aleksandra MączyńskaAMAleksandra Mączyńska
- Noor Alhuda Al-KarawiNANoor Alhuda Al-Karawi
- Paulina KędziorekPKPaulina Kędziorek
- Zuzanna TançZTZuzanna Tanç
Open Access
- 6 January 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Abstract
Ryanodine receptor 1-related myopathies (RYR1-RM) constitute the most prevalent class of non-dystrophic congenital myopathies, representing a complex intersection of genetic heterogeneity, molecular pathology, and evolving therapeutic paradigms. Characterized by mutations in the RYR1 gene, these disorders manifest across a broad clinical spectrum ranging from static congenital weakness to life-threatening pharmacogenetic traits such as Malignant Hyperthermia Susceptibility (MHS). This review article provides an exhaustive synthesis of the scientific and societal landscape of RYR1-RM as of 2025. We provide a deep mechanistic analysis of the RyR1 channel's structure-function relationship, elucidated through recent cryo-electron microscopy breakthroughs that define the "leaky channel" pathophysiology. We critically evaluate the emerging pharmacological arsenal, including the landmark Phase 1b trial of the Rycal compound ARM210 (S48168), the novel application of epigenetic modulation via 5-aza-2'-deoxycytidine, and the repurposed utility of dantrolene and salbutamol. Furthermore, we dissect the frontier of precision genetic engineering, detailing the mechanics and efficacy of Prime Editing and Twin Prime Editing strategies, alongside the development of myotropic viral vectors (MyoAAV) designed to overcome the delivery barriers inherent to the massive RYR1 gene. Beyond the bench, this report integrates a rigorous social science perspective, analyzing the health economic frameworks (ICER, QALYs) that govern access to orphan drugs, the ethical dimensions of somatic gene editing for non-lethal disabilities, and the transformative role of patient advocacy in the rare disease ecosystem. This multidimensional review aims to serve as a foundational resource for clinicians, researchers, and policymakers navigating the complex transition from supportive care to disease-modifying precision medicine.Keywords
This publication has 33 references indexed in Scilit:
- Myopathic manifestations across the adult lifespan of patients with malignant hyperthermia susceptibility: a narrative reviewBritish Journal of Anaesthesia, 2024
- Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trialeClinicalMedicine, 2024
- Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across speciesCell, 2021
- Correlation of phenotype with genotype and protein structure in RYR1-related disordersJournal of Neurology, 2018
- RYR1-related rhabdomyolysis: A common but probably underdiagnosed manifestation of skeletal muscle ryanodine receptor dysfunctionRevue Neurologique, 2016
- 217th ENMC International Workshop: RYR1-related myopathies, Naarden, The Netherlands, 29–31 January 2016Neuromuscular Disorders, 2016
- Cost of illness for neuromuscular diseases in the United StatesMuscle & Nerve, 2013
- Congenital myopathies – Clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United KingdomNeuromuscular Disorders, 2013
- Ryanodine Receptor Oxidation Causes Intracellular Calcium Leak and Muscle Weakness in AgingCell Metabolism, 2011
- RyR1 S-Nitrosylation Underlies Environmental Heat Stroke and Sudden Death in Y522S RyR1 Knockin MiceCell, 2008